Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Landewé, Robert B M ^a,b   Connell, Carol A ^c   Bradley, John D ^c   Wilkinson, Bethanie ^c   Gruben, David ^c   Strengholt, Sander ^c   van der Heijde, Désirée ^d  

^a Academic Center Amsterdam   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c PFIZER INC   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Missing data; Modified total Sharp score; Outlier; Prognostic factors; Radiographic progression; Rheumatoid arthritis; Sensitivity analyses; Tofacitinib

Indexed keywords

METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; TOFACITINIB;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PARALLEL DESIGN; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VAN DER HEIJDE MODIFIED TOTAL SHARP SCORE;

EID: 84988643037     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1106-y     Document Type: Article

References (28)

1. Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis. 2011;70:1631-40.
2. American College of Rheumatology Rheumatoid Arthritis Clinical Trials Task Force Imaging Group and Outcome Measures in Rheumatology Magnetic Resonance Imaging Inflammatory Arthritis Working Group. Review: the utility of magnetic resonance imaging for assessing structural damage in randomized controlled trials in rheumatoid arthritis. Arthritis Rheum. 2013;65:2513-23.
3. Landewe R, Strand V, van der Heijde D. From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. Ann Rheum Dis. 2013;72:1113-7.
4. European Medicines Agency, CPMP. Points to consider on clinical investigation of medicinal products other than NSAIDs for treatment of rheumatoid arthritis. 2003. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003439.pdf. Accessed 1 Mar 2016.
5. American College of Rheumatology Rheumatoid Arthritis Clinical Trial Investigators Ad Hoc Task Force. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis Rheum. 2011;63:2151-6.
6. Genovese MC, Jarosova K, Cieslak D, Alper J, Kivitz A, Hough DR, et al. Apremilast in patients with active rheumatoid arthritis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2015;67:1703-10.
7. Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis. 2014;73:2152-9.
8. Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63:1200-10.
9. Markusse IM, Landewe R, Wolterbeek R, Ho M, Jenkins M, van der Heijde D. Linear extrapolation of missing radiographic change scores in clinical trials does not spuriously overestimate group radiographic changes in rheumatoid arthritis. Rheumatology (Oxford). 2016;55(7):1295-300.
10. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27:261-3.
11. Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:92.
12. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559-70.
13. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377-86.
14. Landewe R, van der Heijde D, Connell C, Bradley J, Gruben D, Brown M. Trimmed analyses, a new approach to the analysis of sharp score data in the assessment of progression in patients with rheumatoid arthritis. Poster presented at the American College of Rheumatology Annual Meeting, Washington DC, 2012
15. Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65:453-8.
16. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis. 2005;64:196-201.
17. Courvoisier N, Dougados M, Cantagrel A, Goupille P, Meyer O, Sibilia J, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2008;10:R106.
18. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford). 2007;46:342-9.
19. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114-21.
20. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis. 2010;69:1333-7.
21. Chen T, Tang W, Lu Y, Tu X. Rank regression: an alternative regression approach for data with outliers. Shanghai Arch Psych. 2014;26:310-5.
22. Lee AH, Gracey M, Wang K, Yau KK. A robustified modeling approach to analyze pediatric length of stay. Ann Epidemiol. 2005;15:673-7.
23. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.
24. Guillemin F, Gerard N, van Leeuwen M, Smedstad LM, Kvien TK, van den Heuvel W. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. J Rheumatol. 2003;30:2585-9.
25. Fautrel B, Granger B, Combe B, Saraux A, Guillemin F, Le Loet X. Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort. Arthritis Res Ther. 2012;14:R249.
26. Lillegraven S, Paynter N, Prince FH, Shadick NA, Haavardsholm EA, Frits ML, et al. Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65:526-33.
27. Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis. 2016;75:75-83.
28. Food and Drug Administration. Guidance for industry: rheumatoid arthritis: developing drug products for treatment. 2013. p. 1-11.